Jefferies Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Jefferies Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.42M	Buy	190,200 +111,220	+141%	+$2.1M	0.02%	505
2026 Q1	$1.72M	Buy	+78,980	New	+$1.53M	0.01%	691
2025 Q3	–	Sell	-1,068	Closed	-$18.3K	–	1669
2025 Q2	$18.3K	Buy	+1,068	New	+$45.6K	﹤0.01%	1225
2024 Q2	–	Sell	-7,800	Closed	-$1.01M	–	1849
2024 Q1	$1.01M	Sell	7,800 -57,933	-88%	-$7.1M	0.01%	822
2023 Q4	$6.34M	Buy	+65,733	New	+$6.31M	0.04%	332
2023 Q3	–	Sell	-3,494	Closed	-$395K	–	1967
2023 Q2	$400K	Sell	3,494 -3,463	-50%	-$447K	﹤0.01%	1248
2023 Q1	$959K	Sell	6,957 -62,335	-90%	-$8.09M	0.01%	911
2022 Q4	$8.98M	Buy	+69,292	New	+$8.03M	0.06%	236

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jefferies Financial Group's SRPT Position: Q2 2026 in Review

Jefferies Financial Group increased its Sarepta Therapeutics (SRPT) stake by 141% in Q2 2026, buying an estimated $2.1M and bringing the position to 190,200 shares worth $3.42M. The position accounts for 0.02% of the portfolio, ranked #505.

Jefferies Financial Group first reported a position in SRPT in Q4 2022 and has held it in 8 quarters since. The position peaked at $8.98M in Q4 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Jefferies Financial Group held 190,200 shares of Sarepta Therapeutics worth $3.42M as of Q2 2026.
Jefferies Financial Group bought 111,220 Sarepta Therapeutics shares in Q2 2026, an estimated $2.1M.
Sarepta Therapeutics made up 0.02% of Jefferies Financial Group's portfolio in Q2 2026, its #505 holding.
Jefferies Financial Group first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 8 quarters since.
Jefferies Financial Group's Sarepta Therapeutics position peaked at $8.98M in Q4 2022.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.